Gift Mulima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gift Mulima has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Katherine Van Loon
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
14 shared publications - Bongani Kaimila
UNC Project-Malawi, Lilongwe, Malawi
13 shared publications - Dianna L. Ng
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
13 shared publications - Satish Gopal
UNC Project-Malawi, Lilongwe, Malawi
13 shared publications - Ally Mwanga
Department of Surgery, Muhimbili University of Health and Allied Sciences, Dar Es Salaam, Tanzania
12 shared publications - Amie Radenbaugh
NantOmics/NantHealth, Inc., El Segundo, California
12 shared publications
Latest Publications
- 12 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 19 (4) , 197-201
Validation of Methylated DNA Markers for Esophageal Squamous Cancer: An International Study
Esophageal squamous cell carcinoma (ESCC) remains a leading cause of cancer-related mortality worldwide, and there are limited molecular screening options. Following a prior discovery and validation studies in subjects from the United States, China, and Iran, we aimed to validate methylated DNA markers (MDM) for ESCC detection in Malawi, a country with one of the highest ESCC incidence. Fourteen MDMs were tested on 177 tissue samples. Ten MDMs showed excellent performance (AUCs ≥ 0.85); a random forest model achieved an AUC of 0.97. The consistent cross-population performance suggests potential for universal application of these MDMs and further justifies exploring nonendoscopic sampling methods, such as swallowed cell collection devices in combination with MDMs, for efficient and cost-effective screening in high-incidence populations. Prevention Relevance: This study validates MDMs for early detection of ESCC in Malawi, supporting their potential role in noninvasive, population-based screening strategies in Africa to enable early detection and timely intervention for cancer interception, potentially reducing cancer burden in high-incidence, resource-limited regions.
- 12 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 19 (4) , 197-201
Validation of Methylated DNA Markers for Esophageal Squamous Cancer: An International Study
Esophageal squamous cell carcinoma (ESCC) remains a leading cause of cancer-related mortality worldwide, and there are limited molecular screening options. Following a prior discovery and validation studies in subjects from the United States, China, and Iran, we aimed to validate methylated DNA markers (MDM) for ESCC detection in Malawi, a country with one of the highest ESCC incidence. Fourteen MDMs were tested on 177 tissue samples. Ten MDMs showed excellent performance (AUCs ≥ 0.85); a random forest model achieved an AUC of 0.97. The consistent cross-population performance suggests potential for universal application of these MDMs and further justifies exploring nonendoscopic sampling methods, such as swallowed cell collection devices in combination with MDMs, for efficient and cost-effective screening in high-incidence populations. Prevention Relevance: This study validates MDMs for early detection of ESCC in Malawi, supporting their potential role in noninvasive, population-based screening strategies in Africa to enable early detection and timely intervention for cancer interception, potentially reducing cancer burden in high-incidence, resource-limited regions.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa
Supplementary Figure S2. Expression of Mutsig CV genes in cohorts from Tanzania (Panel A) and Malawi (Panel B).
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa
Supplementary Figure S2. Expression of Mutsig CV genes in cohorts from Tanzania (Panel A) and Malawi (Panel B).
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa
Supplementary Figure S1. Measurement of RNA Quantity and Quality using PAXgene tissue container vs. RNAlater.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa
Supplementary Figure S1. Measurement of RNA Quantity and Quality using PAXgene tissue container vs. RNAlater.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa
Background:Esophageal squamous cell carcinoma (ESCC) comprises 90% of all esophageal cancer cases globally and is the most common histology in low-resource settings. Eastern Africa has a disproportionately high incidence of ESCC.Methods:We describe the genomic profiles of 61 ESCC cases from Tanzania and compare them to profiles from an existing cohort of ESCC cases from Malawi. We also provide a comparison to ESCC tumors in The Cancer Genome Atlas (TCGA).Results:We observed substantial transcriptional overlap with other squamous histologies via comparison with TCGA PanCan dataset. DNA analysis revealed known mutational patterns, both genome-wide as well as in genes known to be commonly mutated in ESCC. TP53 mutations were the most common somatic mutation in tumors from both Tanzania and Malawi but were detected at lower frequencies than previously reported in ESCC cases from other settings. In a combined analysis, two unique transcriptional clusters were identified: a proliferative/epithelial cluster and an invasive/migrative/mesenchymal cluster. Mutational signature analysis of the Tanzanian cohort revealed common signatures associated with aging and cytidine deaminase activity (APOBEC) and an absence of signature 29, which was previously reported in the Malawi cohort.Conclusions:This study defines the molecular characteristics of ESCC in Tanzania, and enriches the Eastern African dataset, with findings of overall similarities but also some heterogeneity across two unique sites.Impact:Despite a high burden of ESCC in Eastern Africa, investigations into the genomics in this region are nascent. This represents the largest comprehensive genomic analysis ESCC from sub-Saharan Africa to date.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa
Background:Esophageal squamous cell carcinoma (ESCC) comprises 90% of all esophageal cancer cases globally and is the most common histology in low-resource settings. Eastern Africa has a disproportionately high incidence of ESCC.Methods:We describe the genomic profiles of 61 ESCC cases from Tanzania and compare them to profiles from an existing cohort of ESCC cases from Malawi. We also provide a comparison to ESCC tumors in The Cancer Genome Atlas (TCGA).Results:We observed substantial transcriptional overlap with other squamous histologies via comparison with TCGA PanCan dataset. DNA analysis revealed known mutational patterns, both genome-wide as well as in genes known to be commonly mutated in ESCC. TP53 mutations were the most common somatic mutation in tumors from both Tanzania and Malawi but were detected at lower frequencies than previously reported in ESCC cases from other settings. In a combined analysis, two unique transcriptional clusters were identified: a proliferative/epithelial cluster and an invasive/migrative/mesenchymal cluster. Mutational signature analysis of the Tanzanian cohort revealed common signatures associated with aging and cytidine deaminase activity (APOBEC) and an absence of signature 29, which was previously reported in the Malawi cohort.Conclusions:This study defines the molecular characteristics of ESCC in Tanzania, and enriches the Eastern African dataset, with findings of overall similarities but also some heterogeneity across two unique sites.Impact:Despite a high burden of ESCC in Eastern Africa, investigations into the genomics in this region are nascent. This represents the largest comprehensive genomic analysis ESCC from sub-Saharan Africa to date.
- 1 November 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2500221
Treatment Outcomes of Esophageal Cancer in Malawi: An Analysis of Overall Survival and Patient-Reported Outcomes
PURPOSE: Esophageal squamous cell carcinoma (ESCC) is a prevalent cancer in eastern Africa. Optimal management strategies in eastern Africa have not been well established. This study aimed to evaluate ESCC treatment outcomes at Kamuzu Central Hospital (KCH), a national cancer center in Malawi. METHODS: This prospective, observational, cohort study was conducted as part of a multicenter collaboration within the African Esophageal Cancer Consortium (ClinicalTrials.gov identifier: NCT05177393 ). Patients who presented to KCH with esophageal cancer (EC) were recruited from June 2021 to December 2022. Data on patient and treatment characteristics were collected using interviews and chart review. Mobile phone outreach was used to assess patient-reported outcomes (PROs). PROs were analyzed using linear mixed modeling. Kaplan-Meier method with log-rank test and Cox proportional hazards regression were used to evaluate overall survival by treatment group. RESULTS: A total of 148 of 150 eligible patients enrolled. Of 114 with biopsy-proven EC, 97% (n = 111) had ESCC. Most were documented as having localized disease; however, 56% did not complete staging imaging. Forty-seven percent received supportive care, 30% self-expandable metallic stent (SEMS), 20% chemotherapy, and 3% SEMS plus chemotherapy. SEMS was associated with the highest proportion experiencing dysphagia improvement (SEMS 68% v chemotherapy 63% v supportive care 39%). Twelve-month survival rate was the highest in the chemotherapy arm (29% v supportive care 19% v SEMS 6%, log-rank P = .018). CONCLUSION: ESCC remains a highly fatal malignancy in Malawi. Most patients at KCH are treated with SEMS or supportive care. Although data must be interpreted with caution given likely confounding, chemotherapy was associated with the highest 12-month survival rate as compared with SEMS and supportive care, whereas SEMS was associated with the highest likelihood of improved dysphagia.
- 1 November 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2500221
Treatment Outcomes of Esophageal Cancer in Malawi: An Analysis of Overall Survival and Patient-Reported Outcomes
PURPOSE: Esophageal squamous cell carcinoma (ESCC) is a prevalent cancer in eastern Africa. Optimal management strategies in eastern Africa have not been well established. This study aimed to evaluate ESCC treatment outcomes at Kamuzu Central Hospital (KCH), a national cancer center in Malawi. METHODS: This prospective, observational, cohort study was conducted as part of a multicenter collaboration within the African Esophageal Cancer Consortium (ClinicalTrials.gov identifier: NCT05177393 ). Patients who presented to KCH with esophageal cancer (EC) were recruited from June 2021 to December 2022. Data on patient and treatment characteristics were collected using interviews and chart review. Mobile phone outreach was used to assess patient-reported outcomes (PROs). PROs were analyzed using linear mixed modeling. Kaplan-Meier method with log-rank test and Cox proportional hazards regression were used to evaluate overall survival by treatment group. RESULTS: A total of 148 of 150 eligible patients enrolled. Of 114 with biopsy-proven EC, 97% (n = 111) had ESCC. Most were documented as having localized disease; however, 56% did not complete staging imaging. Forty-seven percent received supportive care, 30% self-expandable metallic stent (SEMS), 20% chemotherapy, and 3% SEMS plus chemotherapy. SEMS was associated with the highest proportion experiencing dysphagia improvement (SEMS 68% v chemotherapy 63% v supportive care 39%). Twelve-month survival rate was the highest in the chemotherapy arm (29% v supportive care 19% v SEMS 6%, log-rank P = .018). CONCLUSION: ESCC remains a highly fatal malignancy in Malawi. Most patients at KCH are treated with SEMS or supportive care. Although data must be interpreted with caution given likely confounding, chemotherapy was associated with the highest 12-month survival rate as compared with SEMS and supportive care, whereas SEMS was associated with the highest likelihood of improved dysphagia.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa
Supplementary Figure S1. Measurement of RNA Quantity and Quality using PAXgene tissue container vs. RNAlater.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa
Supplementary Figure S1. Measurement of RNA Quantity and Quality using PAXgene tissue container vs. RNAlater.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa
Supplementary Figure S2. Expression of Mutsig CV genes in cohorts from Tanzania (Panel A) and Malawi (Panel B).
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa
Supplementary Figure S2. Expression of Mutsig CV genes in cohorts from Tanzania (Panel A) and Malawi (Panel B).
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa
Supplementary Figure S1. Measurement of RNA Quantity and Quality using PAXgene tissue container vs. RNAlater.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa
Supplementary Figure S1. Measurement of RNA Quantity and Quality using PAXgene tissue container vs. RNAlater.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa
Supplementary Figure S2. Expression of Mutsig CV genes in cohorts from Tanzania (Panel A) and Malawi (Panel B).
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa
Supplementary Figure S2. Expression of Mutsig CV genes in cohorts from Tanzania (Panel A) and Malawi (Panel B).
- Open Access
- 1 March 2024
- Published by Taylor & Francis in Traffic Injury Prevention
- Vol. 25 (3) , 313-321
Recommendations for effective collaboration and capacity building in epidemiological studies on the effect of alcohol and drug use on traffic safety in low- and middle-income countries
Alcohol or drug impairment is a major risk factor for road traffic crashes, and studies on this issue are essential to provide evidence-based data for policymakers. In low- and middle-income countries (LMICs), such studies are often conducted in partnership with one or more organizations in high-income countries (HICs). The aim of this article is to provide recommendations for improving project planning and decision-making processes in epidemiological studies on alcohol, drug and traffic safety in LMICs involving HICs. We searched Pubmed, Google Scholar, and Google Search for articles and reports in English about lessons learned when conducting collaborative research in LMIC as well as papers presenting recommendations for effective research collaboration with partners in LMICs. Based on the search results, we selected 200 papers for full text examination. Few were related to studies on the effect of alcohol or drug use on road traffic safety. However, several conclusions and recommendations from other studies were found to be relevant. We combined the findings with our own experience in a narrative review. We also present a checklist for risk and quality assessment. Many papers presented similar recommendations, which included the importance of addressing local needs, ensuring adequate resources, local project ownership and leadership, establishing strong partnerships among all involved stakeholders, promoting shared decision-making and planning, and implementing strategies to translate research findings into policy, practice, and publications. It is also important to avoid HIC bias, which prioritizes the interests or perspectives of HICs over those of LMICs.
- 1 March 2024
- Published by Taylor & Francis in Traffic Injury Prevention
- Vol. 25 (3) , 313-321
Open AccessRecommendations for effective collaboration and capacity building in epidemiological studies on the effect of alcohol and drug use on traffic safety in low- and middle-income countries
Alcohol or drug impairment is a major risk factor for road traffic crashes, and studies on this issue are essential to provide evidence-based data for policymakers. In low- and middle-income countries (LMICs), such studies are often conducted in partnership with one or more organizations in high-income countries (HICs). The aim of this article is to provide recommendations for improving project planning and decision-making processes in epidemiological studies on alcohol, drug and traffic safety in LMICs involving HICs. We searched Pubmed, Google Scholar, and Google Search for articles and reports in English about lessons learned when conducting collaborative research in LMIC as well as papers presenting recommendations for effective research collaboration with partners in LMICs. Based on the search results, we selected 200 papers for full text examination. Few were related to studies on the effect of alcohol or drug use on road traffic safety. However, several conclusions and recommendations from other studies were found to be relevant. We combined the findings with our own experience in a narrative review. We also present a checklist for risk and quality assessment. Many papers presented similar recommendations, which included the importance of addressing local needs, ensuring adequate resources, local project ownership and leadership, establishing strong partnerships among all involved stakeholders, promoting shared decision-making and planning, and implementing strategies to translate research findings into policy, practice, and publications. It is also important to avoid HIC bias, which prioritizes the interests or perspectives of HICs over those of LMICs.